ArticleInvestigative ophthalmology & visual science2026
Aspergillus Endophthalmitis: Clinical Features, Treatment Modalities, and Visual Outcomes.
Article in Investigative ophthalmology & visual science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The purpose of this study was to evaluate clinical features, treatment modalities, and visual outcomes of Aspergillus endophthalmitis in a tertiary referral center. Methods: This was a retrospective consecutive case series of patients with Aspergillus endophthalmitis treated at Bascom Palmer Eye Institute from October 2014 to December 2025. Demographics, infection source, microbiologic findings, presenting features, treatments, complications, and best-corrected visual acuity (BCVA) outcomes were reviewed. Results: Fourteen eyes of 14 patients were included; median age was 62 years, and 10 patients (71%) were men. Nine eyes (64%) had exogenous disease and five (36%) had endogenous disease. Aspergillus infection was culture-proven in 12 eyes (86%) and presumed clinically in 2 (14%); identified species included A. fumigatus, A. flavus, and A. niger. Median presenting BCVA was 2.40 logMAR (approximately hand motion), and vitritis was present in all eyes. All eyes received intravitreal therapy, most commonly voriconazole (71%); systemic antifungal therapy was administered in 79%. Pars plana vitrectomy (PPV) was performed in 12 eyes (86%), including repeat PPV in 4. Median follow-up was 554 days. Final median BCVA was 2.70 logMAR (approximately light perception). Only 1 eye (7%) achieved 20/200 or better, whereas 7 eyes (50%) had final light perception or no light perception vision. Phthisis developed in three eyes (21%), and no eyes underwent evisceration or enucleation. Conclusions: Aspergillus endophthalmitis was associated with poor visual outcomes despite multimodal therapy. Exogenous and endogenous cases showed distinct clinical patterns, supporting early microbiologic diagnosis, timely antifungal therapy, and individualized surgical intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.